FATE Gets FDA Fast Track Status

FATE shares have increased over 20% after the company said the FDA has granted Fast Track status to ProTmune, its drug for the reduction of the incidence and severity of acute graft-versus-host disease (GvHD). The company also announced that Phase 1/2 clinical trial of ProTmune in adult subjects with hematologic malignancies is open for patient enrollment. FATE shares are currently trading at $2.17 with over 2.5 million shares traded.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline is comprised of immuno-oncology programs, including off-the-shelf NK- and T-cell cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for regulating autoimmunity.

SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ProTmune™ for the reduction of incidence and severity of acute graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). In addition, the Company announced that its multi-center, randomized, controlled Phase 1/2 clinical trial of ProTmune in adult subjects with hematologic malignancies is open for patient enrollment.

“The Fast Track designation for ProTmune underscores the significant need to address life-threatening immunological conditions which compromise the curative potential of allogeneic hematopoietic cell transplantation,” said Chris Storgard, M.D., Chief Medical Officer of Fate Therapeutics. “Acute graft-versus-host disease is a leading cause of morbidity and mortality in allogeneic HCT recipients. There is no approved preventive therapy, and current treatments suppress immune function and place high-risk immunocompromised patients at even greater risk for severe infections. We look forward to continuing to work with the FDA to rapidly advance our novel immunotherapy through the clinical development and regulatory processes, with the aim of bringing a transformative therapy to patients in an expedited time frame.”

Fate Therapeutics is currently investigating ProTmune in an open-label Phase 1/2 clinical trial for the prevention of acute GvHD and cytomegalovirus (CMV) infection, both of which are leading causes of morbidity and mortality in patients undergoing HCT. The multi-center clinical trial design consists of an initial 10-subject, Phase 1 stage, during which all subjects undergoing allogeneic mobilized peripheral blood (mPB) HCT will receive ProTmune. Following an independent data monitoring committee safety review, a 60-subject, randomized, controlled Phase 2 stage is expected to enroll, during which subjects undergoing allogeneic mPB HCT will be assigned to receive either ProTmune or a conventional mPB cell graft in a 1:1 ratio.

The Fast Track Designation is designed to facilitate development and expedite review of experimental therapies that address the unmet medical needs of patients with serious conditions. Acute GvHD usually occurs within the first several months post-HCT when newly-transplanted donor immune cells recognize the patient’s body as foreign and attack the patient’s tissue. Despite the use of protocols to reduce the incidence of acute GvHD, up to 50 percent of HCT recipients still experience the debilitating disease. Additionally, only about half of patients with acute GVHD durably respond to its treatment. There are approximately 30,000 allogeneic HCT procedures performed globally each year according to the Center for International Blood and Marrow Transplant Research.

About ProTmune™

ProTmune™ is an investigational programmed cellular immunotherapy undergoing clinical development for the prevention of acute GvHD and CMV infection in patients undergoing allogeneic HCT. The cell therapy is produced by modulating a donor-sourced, mobilized peripheral blood graft ex vivo with two small molecules (FT1050 and FT4145) to enhance the biological properties and therapeutic function of the graft’s immune cells. The programmed mobilized peripheral blood graft is adoptively transferred and administered to a patient as a one-time intravenous infusion.

About Us

Created for active traders, Traders News Source is dedicated to being your number one source of breaking market news. Not only do we bring you top stories in key sectors, we give you well-researched expert reviews of specific opportunities in hot sectors like biotech, energy, new technology and more.